Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Phase I trial of dendritic cell vaccine in patients with colorectal cancer meets endpoint
February 27th, 2006
Researchers from the University of California at San Francisco reported at the 2006 ASCO Gastrointestinal Cancers Symposium on results of a phase I trial of IDM Pharma, Inc.'s (IDMI) Collidem dendritic cell vaccine for colorectal cancer. In this trial, patients with advanced colorectal cancer who had failed standard therapies were vaccinated with dendritic cells loaded with a cocktail of immunogenic peptides (epitopes) derived from well characterized tumor antigens. Intradermal administration of the vaccine was well tolerated with only mild injection site reactions reported. CD8 antigen specific responses were observed in a subset of patients that...
Source: Pharma Business Week (2006-02-27)
|
